Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience

This review of the literature, and the authors' own decade of experience with lutetium-177-octreotate-capecitabine±temozolomide peptide receptor radionuclide therapy (PRRT)-chemotherapy of GEPNETs, analyses the risk of both short- and long-term hematotoxicity. Myelodysplastic syndrome (MDS) and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer biotherapy & radiopharmaceuticals 2016-08, Vol.31 (6), p.189-198
Hauptverfasser:	Kesavan, Murali, Turner, J Harvey
Format:	Artikel
Sprache:	eng
Schlagworte:	Capecitabine - adverse effects Capecitabine - therapeutic use Dacarbazine - adverse effects Dacarbazine - analogs & derivatives Dacarbazine - therapeutic use Female Humans Lutetium - adverse effects Lutetium - therapeutic use Male Middle Aged Myelodysplastic Syndromes - etiology Neuroendocrine Tumors - radiotherapy Octreotide - adverse effects Octreotide - analogs & derivatives Octreotide - therapeutic use Radiation Injuries - etiology Radioisotopes - adverse effects Radioisotopes - therapeutic use Radiopharmaceuticals - administration & dosage Radiopharmaceuticals - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!